Synergy Pharmaceuticals to Present Abstract at Digestive Disease Week 2012
May 15 2012 - 9:15AM
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU)
(Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal
disorders and diseases, today announced that a poster presentation
will be given at the Digestive Disease Week 2012 Conference which
is being held in San Diego, CA from May 19 through May 22, 2012.
The poster presentation is Sunday, May 20, 8:00 am to 5:00 pm at
the San Diego Convention Center.
Poster Su1189: Identification of Cardinal
Symptoms in Patients with Chronic Idiopathic Constipation (CIC).
Alan Joslyn1, Laura Barrow1, Gary S. Jacob1 and Jean Paty2
1Synergy Pharmaceuticals, 420 Lexington Ave., Suite 1609, New
York, NY, USA; 2PRO Consulting, 2100 Wharton Street, Suite
505, Pittsburgh, PA 15203
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's lead proprietary drug candidate plecanatide is
a synthetic analog of the human gastrointestinal hormone
uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a
Phase I study of plecanatide in healthy volunteers and a Phase IIa
clinical trial in CIC patients. In October, 2011, Synergy initiated
dosing of patients in a major Phase II/III clinical trial of
plecanatide to treat chronic idiopathic constipation. Plecanatide
is also being developed to treat IBS-C, with the first trial in
IBS-C patients planned for 2H2012. Synergy's second GC-C agonist
SP-333 is currently in pre-clinical development to treat
inflammatory bowel diseases. More information is available at
http://www.synergypharma.com.
CONTACT: Investor Contact Information:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Historical Stock Chart
From Apr 2023 to Apr 2024